GB0000313D0 - Formulation - Google Patents

Formulation

Info

Publication number
GB0000313D0
GB0000313D0 GBGB0000313.7A GB0000313A GB0000313D0 GB 0000313 D0 GB0000313 D0 GB 0000313D0 GB 0000313 A GB0000313 A GB 0000313A GB 0000313 D0 GB0000313 D0 GB 0000313D0
Authority
GB
United Kingdom
Prior art keywords
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0000313.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26243352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0000313(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Priority to GBGB0000313.7A priority Critical patent/GB0000313D0/en
Publication of GB0000313D0 publication Critical patent/GB0000313D0/en
Priority to GBGB0008837.7A priority patent/GB0008837D0/en
Priority to ES10180667.7T priority patent/ES2543384T3/es
Priority to HK03101532.0A priority patent/HK1049286B/en
Priority to BRPI0107445-8A priority patent/BR0107445B1/pt
Priority to SI200130446T priority patent/SI1250138T2/sl
Priority to PT101806677T priority patent/PT2266573E/pt
Priority to EG20010017A priority patent/EG24074A/xx
Priority to HK03105241.3A priority patent/HK1052884B/zh
Priority to EP01900186.6A priority patent/EP1250138B2/en
Priority to CNB018035469A priority patent/CN1222292C/zh
Priority to RU2002121507A priority patent/RU2263507C9/ru
Priority to EP05016921A priority patent/EP1669073A3/en
Priority to ES01900186.6T priority patent/ES2248272T5/es
Priority to PL356030A priority patent/PL202525B1/pl
Priority to JP2001551480A priority patent/JP3713237B2/ja
Priority to CA002351004A priority patent/CA2351004C/en
Priority to KR1020027008855A priority patent/KR100802366B1/ko
Priority to DE60114145.8T priority patent/DE60114145T3/de
Priority to HU0204137A priority patent/HU230162B1/hu
Priority to PCT/GB2001/000049 priority patent/WO2001051056A1/en
Priority to MXPA02006698A priority patent/MXPA02006698A/es
Priority to US10/169,777 priority patent/US20030125387A1/en
Priority to DK01900186.6T priority patent/DK1250138T4/en
Priority to EEP200200387A priority patent/EE05421B1/xx
Priority to IL15023001A priority patent/IL150230A0/xx
Priority to SI200131044T priority patent/SI2266573T1/sl
Priority to AT01900186T priority patent/ATE306928T1/de
Priority to SK984-2002A priority patent/SK287221B6/sk
Priority to AU23863/01A priority patent/AU762080B2/en
Priority to GB0100407A priority patent/GB2359254B/en
Priority to EP10180667.7A priority patent/EP2266573B1/en
Priority to EP10180661.0A priority patent/EP2286818B1/en
Priority to DK10180667.7T priority patent/DK2266573T3/en
Priority to CZ2002-2384A priority patent/CZ304689B6/cs
Priority to US09/756,291 priority patent/US6774122B2/en
Priority to BE2001/0021A priority patent/BE1013477A3/fr
Priority to IT000005A priority patent/ITTO20010005A1/it
Priority to PT102548A priority patent/PT102548A/pt
Priority to DE10100779A priority patent/DE10100779A1/de
Priority to ES200100057A priority patent/ES2186517B2/es
Priority to ARP010100100A priority patent/AR027510A1/es
Priority to MYPI20010107A priority patent/MY118583A/en
Priority to IT2001TO000008A priority patent/ITTO20010008A1/it
Priority to CO01001317A priority patent/CO5280206A1/es
Priority to TW090100514A priority patent/TWI259086B/zh
Priority to CH00029/01A priority patent/CH696260A5/de
Priority to NL1017075A priority patent/NL1017075C2/nl
Priority to FR0100248A priority patent/FR2803516B1/fr
Priority to UA2002086628A priority patent/UA75879C2/uk
Priority to ZA200204165A priority patent/ZA200204165B/xx
Priority to IL150230A priority patent/IL150230A/en
Priority to BG106833A priority patent/BG65776B1/bg
Priority to NO20023227A priority patent/NO336286B1/no
Priority to IS6454A priority patent/IS2932B/is
Priority to JP2003362875A priority patent/JP2004107353A/ja
Priority to US10/872,784 priority patent/US7456160B2/en
Priority to US12/285,887 priority patent/US8329680B2/en
Priority to HK11103860.8A priority patent/HK1150021B/en
Priority to JP2011135962A priority patent/JP2011190275A/ja
Priority to US13/602,667 priority patent/US8466139B2/en
Priority to NO20150741A priority patent/NO337329B1/no
Priority to CY20151100648T priority patent/CY1116520T1/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB0000313.7A 2000-01-10 2000-01-10 Formulation Ceased GB0000313D0 (en)

Priority Applications (63)

Application Number Priority Date Filing Date Title
GBGB0000313.7A GB0000313D0 (en) 2000-01-10 2000-01-10 Formulation
GBGB0008837.7A GB0008837D0 (en) 2000-01-10 2000-04-12 Formulation
ES10180667.7T ES2543384T3 (es) 2000-01-10 2001-01-08 Formulación de fulvestrant
HK03101532.0A HK1049286B (en) 2000-01-10 2001-01-08 Fulvestrant formulation
BRPI0107445-8A BR0107445B1 (pt) 2000-01-10 2001-01-08 formulação farmacêutica, e, uso de fulvestrante na preparação de uma formulação farmacêutica.
SI200130446T SI1250138T2 (sl) 2000-01-10 2001-01-08 Formulacije fulvestranta
PT101806677T PT2266573E (pt) 2000-01-10 2001-01-08 Formulação de fulvestrant
EG20010017A EG24074A (en) 2000-01-10 2001-01-08 Formulation
HK03105241.3A HK1052884B (zh) 2000-01-10 2001-01-08 氟维司群制剂
EP01900186.6A EP1250138B2 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
CNB018035469A CN1222292C (zh) 2000-01-10 2001-01-08 氟维司群制剂
RU2002121507A RU2263507C9 (ru) 2000-01-10 2001-01-08 Композиция фульвестранта
EP05016921A EP1669073A3 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
ES01900186.6T ES2248272T5 (es) 2000-01-10 2001-01-08 Formulación de fulvestrant
PL356030A PL202525B1 (pl) 2000-01-10 2001-01-08 Preparat farmaceutyczny fulwestrantu
JP2001551480A JP3713237B2 (ja) 2000-01-10 2001-01-08 フルベストラント製剤
CA002351004A CA2351004C (en) 2000-01-10 2001-01-08 Formulation
KR1020027008855A KR100802366B1 (ko) 2000-01-10 2001-01-08 풀베스트란트 제제
DE60114145.8T DE60114145T3 (de) 2000-01-10 2001-01-08 Fulvestrant formulierung
HU0204137A HU230162B1 (hu) 2000-01-10 2001-01-08 Fulvesztrantot tartalmazó gyógyászati készítmény
PCT/GB2001/000049 WO2001051056A1 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
MXPA02006698A MXPA02006698A (es) 2000-01-10 2001-01-08 Formulacion de fulvestrant.
US10/169,777 US20030125387A1 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
DK01900186.6T DK1250138T4 (en) 2000-01-10 2001-01-08 Fulvestrantformulering
EEP200200387A EE05421B1 (et) 2000-01-10 2001-01-08 Fulvestrandi formulatsioonid
IL15023001A IL150230A0 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
SI200131044T SI2266573T1 (sl) 2000-01-10 2001-01-08 Formulacija fulvestranta
AT01900186T ATE306928T1 (de) 2000-01-10 2001-01-08 Fulvestrant formulierung
SK984-2002A SK287221B6 (sk) 2000-01-10 2001-01-08 Farmaceutická formulácia obsahujúca fulvestrant
AU23863/01A AU762080B2 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
GB0100407A GB2359254B (en) 2000-01-10 2001-01-08 Formulation
EP10180667.7A EP2266573B1 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
EP10180661.0A EP2286818B1 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
DK10180667.7T DK2266573T3 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
CZ2002-2384A CZ304689B6 (cs) 2000-01-10 2001-01-08 Farmaceutický přípravek obsahující fulvestrant a jeho použití pro výrobu léčiva
US09/756,291 US6774122B2 (en) 2000-01-10 2001-01-09 Formulation
BE2001/0021A BE1013477A3 (fr) 2000-01-10 2001-01-09 Formulation.
IT000005A ITTO20010005A1 (it) 2000-01-10 2001-01-09 Formulazione farmaceutica.
PT102548A PT102548A (pt) 2000-01-10 2001-01-09 Formulacao farmaceutica para administracao por injeccao do composto 7alfa-¬9-(4,4,5,5,5-pentafluoropentilsulfinil)-nonil| estra-1,3,5(10)-trieno-3,17beta-diol (fulvestrant)
DE10100779A DE10100779A1 (de) 2000-01-10 2001-01-10 Formulierung
ES200100057A ES2186517B2 (es) 2000-01-10 2001-01-10 Formulacion farmaceutica que contiene fulvestrant.
ARP010100100A AR027510A1 (es) 2000-01-10 2001-01-10 Formulacion
MYPI20010107A MY118583A (en) 2000-01-10 2001-01-10 Formulation
IT2001TO000008A ITTO20010008A1 (it) 2000-01-10 2001-01-10 Formulazione farmaceutica
CO01001317A CO5280206A1 (es) 2000-01-10 2001-01-10 Formulacion farmaceutica de liberacion sostenida adaptada para administracion por inyeccion
TW090100514A TWI259086B (en) 2000-01-10 2001-01-10 Pharmaceutical formulation adapted for intra-muscular injection
CH00029/01A CH696260A5 (de) 2000-01-10 2001-01-10 Fulvestrant Formulierung.
NL1017075A NL1017075C2 (nl) 2000-01-10 2001-01-10 Preparaat.
FR0100248A FR2803516B1 (fr) 2000-01-10 2001-01-10 Formulation injectable de fulvestrant
UA2002086628A UA75879C2 (en) 2000-01-10 2001-08-01 Fulvestrant composition (variants)
ZA200204165A ZA200204165B (en) 2000-01-10 2002-05-24 Fulvestrant formulation.
IL150230A IL150230A (en) 2000-01-10 2002-06-13 Formulation of Fulvestrant
BG106833A BG65776B1 (bg) 2000-01-10 2002-06-18 Фулвестрантов състав
NO20023227A NO336286B1 (no) 2000-01-10 2002-07-03 Fulvestrant-formulering og sprøyte eller glassbeholder inneholdende samme
IS6454A IS2932B (is) 2000-01-10 2002-07-03 Fúlvestrant samsetning
JP2003362875A JP2004107353A (ja) 2000-01-10 2003-10-23 フルベストラント製剤
US10/872,784 US7456160B2 (en) 2000-01-10 2004-06-22 Formulation
US12/285,887 US8329680B2 (en) 2000-01-10 2008-10-15 Formulation
HK11103860.8A HK1150021B (en) 2000-01-10 2011-04-18 Fulvestrant formulation
JP2011135962A JP2011190275A (ja) 2000-01-10 2011-06-20 フルベストラント製剤
US13/602,667 US8466139B2 (en) 2000-01-10 2012-09-04 Formulation
NO20150741A NO337329B1 (no) 2000-01-10 2015-06-08 Anvendelse av fulvestrant-formulering for behandling av brystkreft
CY20151100648T CY1116520T1 (el) 2000-01-10 2015-07-22 Φαρμακοτεχνικη μορφη fulvestrant

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0000313.7A GB0000313D0 (en) 2000-01-10 2000-01-10 Formulation
GBGB0008837.7A GB0008837D0 (en) 2000-01-10 2000-04-12 Formulation
PCT/GB2001/000049 WO2001051056A1 (en) 2000-01-10 2001-01-08 Fulvestrant formulation

Publications (1)

Publication Number Publication Date
GB0000313D0 true GB0000313D0 (en) 2000-03-01

Family

ID=26243352

Family Applications (3)

Application Number Title Priority Date Filing Date
GBGB0000313.7A Ceased GB0000313D0 (en) 2000-01-10 2000-01-10 Formulation
GBGB0008837.7A Ceased GB0008837D0 (en) 2000-01-10 2000-04-12 Formulation
GB0100407A Expired - Lifetime GB2359254B (en) 2000-01-10 2001-01-08 Formulation

Family Applications After (2)

Application Number Title Priority Date Filing Date
GBGB0008837.7A Ceased GB0008837D0 (en) 2000-01-10 2000-04-12 Formulation
GB0100407A Expired - Lifetime GB2359254B (en) 2000-01-10 2001-01-08 Formulation

Country Status (41)

Country Link
US (5) US20030125387A1 (https=)
EP (4) EP1250138B2 (https=)
JP (3) JP3713237B2 (https=)
KR (1) KR100802366B1 (https=)
CN (1) CN1222292C (https=)
AR (1) AR027510A1 (https=)
AT (1) ATE306928T1 (https=)
AU (1) AU762080B2 (https=)
BE (1) BE1013477A3 (https=)
BG (1) BG65776B1 (https=)
BR (1) BR0107445B1 (https=)
CA (1) CA2351004C (https=)
CH (1) CH696260A5 (https=)
CO (1) CO5280206A1 (https=)
CY (1) CY1116520T1 (https=)
CZ (1) CZ304689B6 (https=)
DE (2) DE60114145T3 (https=)
DK (2) DK2266573T3 (https=)
EE (1) EE05421B1 (https=)
EG (1) EG24074A (https=)
ES (3) ES2248272T5 (https=)
FR (1) FR2803516B1 (https=)
GB (3) GB0000313D0 (https=)
HK (2) HK1049286B (https=)
HU (1) HU230162B1 (https=)
IL (2) IL150230A0 (https=)
IS (1) IS2932B (https=)
IT (2) ITTO20010005A1 (https=)
MX (1) MXPA02006698A (https=)
MY (1) MY118583A (https=)
NL (1) NL1017075C2 (https=)
NO (2) NO336286B1 (https=)
PL (1) PL202525B1 (https=)
PT (2) PT2266573E (https=)
RU (1) RU2263507C9 (https=)
SI (2) SI1250138T2 (https=)
SK (1) SK287221B6 (https=)
TW (1) TWI259086B (https=)
UA (1) UA75879C2 (https=)
WO (1) WO2001051056A1 (https=)
ZA (1) ZA200204165B (https=)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
PL367624A1 (en) * 2001-07-07 2005-03-07 Astrazeneca Ab Pharmaceutical formulation for the intramuscular administration of fulvestrant
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
US7217796B2 (en) * 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
TW200404552A (en) * 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
US20050152858A1 (en) * 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
WO2006113483A2 (en) * 2005-04-15 2006-10-26 Schering Corporation Methods and compositions for treating or preventing cancer
SG165404A1 (en) * 2005-09-26 2010-10-28 Hospira Australia Pty Ltd Fulvestrant formulation
RU2338538C1 (ru) * 2007-02-09 2008-11-20 Государственное учебно-научное учреждение Химический факультет Московского государственного университета им. М.В. Ломоносова Антигипотензивное средство
JP2011514349A (ja) * 2008-03-07 2011-05-06 サイドース・エルエルシー フルベストラント配合物
AU2014200332B2 (en) * 2008-04-28 2016-10-06 Diurnal Limited Lipid composition
GB0807605D0 (en) * 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
HUE033581T2 (hu) 2010-06-10 2017-12-28 Seragon Pharmaceuticals Inc Ösztrogén receptor modulátorok és alkalmazásaik
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
CN103221052A (zh) 2010-09-16 2013-07-24 施摩达生物技术有限公司 氟维司群组合物及使用方法
EP2711010B1 (en) * 2011-05-20 2018-10-31 Capital, Business Y Gestión De Finanzas, S.L Pharmaceutical composition
CN102391341B (zh) * 2011-08-09 2013-05-22 福建省微生物研究所 制备6,7-脱氢-17β-烃酰氧基诺龙的方法
CN103070871B (zh) * 2011-10-26 2015-04-15 正大天晴药业集团股份有限公司 一种氟维司群的药物组合物
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
JP6112625B2 (ja) 2011-12-14 2017-04-12 セラゴン ファーマシューティカルズ，インク． フッ素化したエストロゲン受容体モジュレーターおよびその使用
PE20150099A1 (es) 2011-12-16 2015-01-30 Olema Pharmaceuticals Inc Compuestos novedosos de benzopirano, composiciones y usos de los mismos
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
CA2869377C (en) * 2012-04-09 2022-11-08 Scidose, Llc Fulvestrant formulations
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2909418A1 (en) 2013-04-18 2014-10-23 Xi'an Libang Pharmaceutical Technology Co., Ltd. Ester derivative of 7-.alpha.-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)n onyl]-estra-1,3,5(10)-triene-3,17.beta.-diol having anticancer activity and preparation method thereof
WO2014195032A1 (en) 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
CN104337761B (zh) * 2013-08-07 2019-03-26 江苏豪森药业集团有限公司 氟维司群药物组合物
WO2015033302A2 (en) * 2013-09-06 2015-03-12 Salah Uddin Ahmed Fulvestrant compositions
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
JP2017507964A (ja) 2014-03-13 2017-03-23 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーターを用いた治療的組合せ
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
KR102785474B1 (ko) 2014-12-18 2025-03-26 에프. 호프만-라 로슈 아게 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR102710603B1 (ko) 2015-10-01 2024-09-27 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
CN108430454A (zh) 2015-10-13 2018-08-21 西弥斯医疗有限公司 氟维司群组合物
SMT202300018T1 (it) 2015-12-09 2023-03-17 Univ Illinois Downregolatori del recettore degli estrogeni a base di benzotiofene
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
EP3441073B1 (en) * 2016-04-06 2022-02-23 FUJIFILM Corporation Medicinal composition comprising fulvestrant
US9969732B2 (en) 2016-04-08 2018-05-15 Genentech, Inc. Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
IL285928B2 (en) * 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
JP6611932B2 (ja) * 2016-05-31 2019-11-27 富士フイルム株式会社 医薬組成物
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
US20170362228A1 (en) 2016-06-16 2017-12-21 Genentech, Inc. TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
JP7018026B2 (ja) * 2016-06-16 2022-02-09 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ヘテロアリールエストロゲン受容体モジュレーター及びその使用
CN107789320B (zh) * 2016-08-31 2021-06-22 鲁南制药集团股份有限公司 一种氟维司群缓释注射液及其制备工艺
TWI793165B (zh) 2017-09-11 2023-02-21 美商阿托薩醫療公司 製造及使用因多昔芬(endoxifen)之方法
EP3706719A1 (en) 2017-11-08 2020-09-16 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
TW201922291A (zh) 2017-11-16 2019-06-16 瑞士商諾華公司 組合療法
CN111465398A (zh) * 2018-01-31 2020-07-28 富士胶片株式会社 注射用制剂的制造方法
RU2684330C1 (ru) * 2018-02-02 2019-04-08 Закрытое Акционерное Общество "Биокад" Композиции фулвестранта
JP7384903B2 (ja) 2018-05-24 2023-11-21 ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN111035613A (zh) * 2018-10-12 2020-04-21 江苏恒瑞医药股份有限公司 一种包含氟维司群的可注射的药物组合物及其制备方法
CN113677346A (zh) 2018-11-01 2021-11-19 希洛斯医药品股份有限公司 周期蛋白依赖性激酶7(cdk7)的抑制剂
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
KR20220024106A (ko) 2019-05-20 2022-03-03 노파르티스 아게 Mcl-1 억제제 항체-약물 접합체 및 사용 방법
MX2022000203A (es) 2019-07-03 2022-03-22 Atossa Therapeutics Inc Composiciones de liberacion sostenida de endoxifeno.
MX2022000279A (es) 2019-07-07 2022-02-03 Olema Pharmaceuticals Inc Regimenes de antagonistas del receptor de estrogeno.
RU2722988C1 (ru) * 2019-11-19 2020-06-05 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ моделирования проканцерогенного действия фулвестранта на яичники потомства женского пола у лабораторных мышей
EP4074304A4 (en) 2019-12-11 2024-01-10 Shanghai Bocimed Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION OF FULVESTRANT, PREPARATION METHOD AND APPLICATION THEREOF
MX2022007759A (es) 2019-12-20 2022-07-19 Novartis Ag Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20240042051A1 (en) 2020-11-24 2024-02-08 Francesca Rocchetti Mcl-1 inhibitor antibody-drug conjugates and methods of use
CA3200858A1 (en) 2020-11-24 2022-06-02 Novartis Ag Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
CN117794929A (zh) 2021-02-02 2024-03-29 法国施维雅药厂 选择性bcl-xl protac化合物及使用方法
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
JP2024545690A (ja) * 2021-12-20 2024-12-10 サムヤン、ホールディングス、コーポレーション 溶解度が改善されたフルベストラントの医薬組成物及びその製造方法
IL317102A (en) 2022-05-20 2025-01-01 Novartis Ag EPHA2 BCL-XL inhibitor antibody-drug conjugates and methods of using them
US20250339547A1 (en) 2022-05-20 2025-11-06 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
AU2024234194A1 (en) 2023-03-10 2025-08-07 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
PY24103486A (es) 2023-11-22 2025-06-06 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
WO2025215536A1 (en) 2024-04-10 2025-10-16 Novartis Ag Macrocyclic panras inhibitors for the treatment of cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB817241A (en) 1957-08-21 1959-07-29 Vismara Francesco Spa Oily solutions for parenteral administration containing adreno-cortical hormones
FR6241E (fr) 1905-04-19 1906-10-10 Ktiengesellschaft Système de refroidissement du piston des moteurs à explosions et des compresseurs
DE947335C (de) 1954-10-19 1956-08-16 Schering Ag Verfahren zur Herstellung stabiler oeliger Loesungen von Oestron
US2983649A (en) 1957-10-15 1961-05-09 Francesco Vismara Societa Per Ricinoleic acid ester solutions of adreno-cortical hormones
GB1060632A (en) * 1962-09-11 1967-03-08 Olin Mathieson Steroid compositions
US3164520A (en) * 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
JPS4327327Y1 (https=) 1965-01-07 1968-11-12
NL151903B (nl) 1965-03-24 1977-01-17 Schering Ag Werkwijze ter bereiding van een injectievloeistof door een steroid op te lossen in een mengsel van ricinusolie en benzylbenzoaat.
USRE28690E (en) * 1965-05-05 1976-01-20 Schering Aktiengesellschaft 17α-Ethinyl-18-methyl-19-nortestosterone esters
GB1207571A (en) * 1967-01-13 1970-10-07 Takeda Chemical Industries Ltd Injectable composition
SU549118A1 (ru) 1973-04-02 1977-03-05 Способ синхронизации половой охоты у циклирующих свиноматок
SU676284A1 (ru) 1975-06-26 1979-07-30 Научно-Исследовательский Институт Животноводства Способ синхронизации половой охоты у самок домашних животных
DE2548413A1 (de) 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4048309A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid ointment formulations
US4048310A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid formulation in form of lotion or cream
NL7711916A (nl) * 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
GB8327256D0 (en) * 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
EP0310542B1 (de) * 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
DE3733478A1 (de) 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
GB8813353D0 (en) 1988-06-06 1988-07-13 Ici Plc Therapeutic product
JPH04327327A (ja) 1991-04-25 1992-11-16 Toyoda Gosei Co Ltd スリーブとホースの加締め用ダイス
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
ZA9510926B (en) * 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
US20010006963A1 (en) 1995-03-16 2001-07-05 Ursula Lachnit-Fixson Once-a-month injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women
DE19510861A1 (de) 1995-03-16 1996-09-19 Schering Ag Einmonatsspritze als Depot-Kontrazeptivum und für die Hormonersatztherapie für peri- und praemenopausale Frauen
EP0760237A1 (en) 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
JPH09208496A (ja) * 1996-01-30 1997-08-12 Takeda Chem Ind Ltd Ｌｈ−ｒｈ拮抗物質含有組成物
DE19613972A1 (de) 1996-04-09 1997-10-16 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
US5952338A (en) 1996-07-05 1999-09-14 Takeda Chemical Industries, Ltd. Agent for prophylaxis and treatment of disturbance of visual function
JPH10203982A (ja) * 1996-07-05 1998-08-04 Takeda Chem Ind Ltd 視機能障害の予防・治療剤
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19638045A1 (de) 1996-09-18 1998-03-19 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen
JPH10152438A (ja) * 1996-11-22 1998-06-09 Takeda Chem Ind Ltd １−アザキサントン誘導体またはその塩の安定化方法および１−アザキサントン誘導体含有組成物
JPH11158200A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd ヒト成長ホルモン・亜鉛複合体及びその用途
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
KR100499438B1 (ko) 1997-12-03 2005-07-07 머크 앤드 캄파니 인코포레이티드 수소화 피마자유를 함유하는 지속성 주사제
EP1985285A3 (en) 1999-04-01 2009-08-12 Hana Biosciences, Inc. Compositions and methods for treating lymphoma
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
JP4327327B2 (ja) 2000-04-03 2009-09-09 ロボテック株式会社 固定スプレー揺動装置
PL367624A1 (en) 2001-07-07 2005-03-07 Astrazeneca Ab Pharmaceutical formulation for the intramuscular administration of fulvestrant
GB0912999D0 (en) 2009-07-27 2009-09-02 Astrazeneca Ab Method-803

Also Published As

Publication number Publication date
US6774122B2 (en) 2004-08-10
AR027510A1 (es) 2003-04-02
SI1250138T2 (sl) 2015-09-30
EP1250138A1 (en) 2002-10-23
BR0107445B1 (pt) 2012-10-30
EG24074A (en) 2008-05-11
HU230162B1 (hu) 2015-09-28
CZ20022384A3 (cs) 2002-09-11
GB2359254A (en) 2001-08-22
RU2263507C2 (ru) 2005-11-10
HK1150021A1 (en) 2011-10-28
CA2351004C (en) 2003-02-18
KR100802366B1 (ko) 2008-02-13
WO2001051056A1 (en) 2001-07-19
BG106833A (en) 2003-03-31
ITTO20010005A0 (it) 2001-01-09
ITTO20010008A0 (it) 2001-01-10
FR2803516A1 (fr) 2001-07-13
FR2803516B1 (fr) 2003-03-28
HK1052884A1 (en) 2003-10-03
SI2266573T1 (sl) 2015-08-31
ITTO20010008A1 (it) 2002-07-10
CN1222292C (zh) 2005-10-12
SK9842002A3 (en) 2003-05-02
JP2011190275A (ja) 2011-09-29
EE200200387A (et) 2003-10-15
EP2266573B1 (en) 2015-06-17
EP1250138B2 (en) 2015-07-08
BR0107445A (pt) 2002-09-17
NO336286B1 (no) 2015-07-13
US7456160B2 (en) 2008-11-25
US8329680B2 (en) 2012-12-11
JP2004107353A (ja) 2004-04-08
NO20023227L (no) 2002-07-03
GB2359254B (en) 2002-06-19
JP2003519659A (ja) 2003-06-24
UA75879C2 (en) 2006-06-15
CO5280206A1 (es) 2003-05-30
EP2266573A1 (en) 2010-12-29
TWI259086B (en) 2006-08-01
EP2286818A1 (en) 2011-02-23
JP3713237B2 (ja) 2005-11-09
EP2286818B1 (en) 2020-03-18
US20120329766A1 (en) 2012-12-27
CZ304689B6 (cs) 2014-09-03
BG65776B1 (bg) 2009-11-30
NL1017075C2 (nl) 2001-09-25
KR20020073499A (ko) 2002-09-26
NO20150741L (no) 2002-07-03
IL150230A (en) 2006-10-31
EP1669073A2 (en) 2006-06-14
GB0008837D0 (en) 2000-05-31
RU2263507C9 (ru) 2020-07-28
PT2266573E (pt) 2015-07-28
NO20023227D0 (no) 2002-07-03
ES2248272T3 (es) 2006-03-16
PT102548A (pt) 2001-07-31
DE60114145D1 (de) 2006-03-02
EE05421B1 (et) 2011-06-15
HK1049286A1 (en) 2003-05-09
US20030125387A1 (en) 2003-07-03
ES2186517A1 (es) 2003-05-01
RU2002121507A (ru) 2004-03-20
ATE306928T1 (de) 2005-11-15
US20100152149A1 (en) 2010-06-17
DK1250138T4 (en) 2015-07-27
ES2186517B2 (es) 2004-03-16
AU762080B2 (en) 2003-06-19
DE60114145T3 (de) 2015-09-17
HUP0204137A2 (hu) 2003-04-28
AU2386301A (en) 2001-07-24
US8466139B2 (en) 2013-06-18
DE60114145T2 (de) 2006-07-13
PL202525B1 (pl) 2009-07-31
HK1052884B (zh) 2006-07-14
HUP0204137A3 (en) 2005-03-29
EP1669073A3 (en) 2008-03-19
ITTO20010005A1 (it) 2001-07-11
DK1250138T3 (da) 2006-01-23
IS6454A (is) 2002-07-03
MY118583A (en) 2004-12-31
GB0100407D0 (en) 2001-02-21
CA2351004A1 (en) 2001-07-10
US20010020016A1 (en) 2001-09-06
EP1250138B1 (en) 2005-10-19
SI1250138T1 (sl) 2006-02-28
BE1013477A3 (fr) 2002-02-05
ES2543384T3 (es) 2015-08-18
SK287221B6 (sk) 2010-03-08
DE10100779A1 (de) 2001-07-26
NO337329B1 (no) 2016-03-14
PL356030A1 (en) 2004-06-14
DK2266573T3 (en) 2015-07-20
MXPA02006698A (es) 2002-09-30
HK1049286B (en) 2006-04-07
ES2248272T5 (es) 2015-08-19
CH696260A5 (de) 2007-03-15
NL1017075A1 (nl) 2001-07-11
IS2932B (is) 2015-12-15
ZA200204165B (en) 2003-10-29
US20050043285A1 (en) 2005-02-24
CY1116520T1 (el) 2017-03-15
IL150230A0 (en) 2002-12-01
CN1394141A (zh) 2003-01-29

Similar Documents

Publication Publication Date Title
EG24074A (en) Formulation
GB0000891D0 (en) Formulation
EG24226A (en) Formulation
AU8420301A (en) Use
GB0015490D0 (en) Novel formulations
GB0025788D0 (en) Use
GB9905898D0 (en) Controlled-dose formulation
GB9902304D0 (en) Formulation
IL154258A0 (en) Fungicidal formulation
GB0125492D0 (en) Formulation
GB9927614D0 (en) Sterliant formulation
GB0005070D0 (en) Use
GB0029634D0 (en) Use
GB2375048B (en) Formulation
GB2396812B (en) Formulation
GB0116619D0 (en) Formulation
GB0001144D0 (en) Glysophosate formulation
GB0023069D0 (en) Formulation
GB0004124D0 (en) Formulation
GB0007112D0 (en) Formulation
GB0010846D0 (en) Formulation
GB0112497D0 (en) Formulation
GB9902236D0 (en) Formulation
GB0022027D0 (en) Disfectant formulations
GB9923538D0 (en) Formulation

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application
AT Applications terminated before publication under section 16(1)